The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...